Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | PHASE1 | ACTIVE NOT_RECRUITING | 113 | — | — | Jan 9, 2023 | Oct 1, 2026 | May 11, 2026 | 18 | China |
ORR is defined as the percentage of participants who had confirmed complete response Complete Response (CR) or Partial Response (PR)
| Arm | Type | Description |
|---|---|---|
| Cohort A: Previously Treated UC | EXPERIMENTAL | BGB-A445 Monotherapy |
| Cohort B: Previously Treated UC | EXPERIMENTAL | BGB-A445 and Tislelizumab |
| Cohort C: Previously Treated RCC | EXPERIMENTAL | BGB-A445 Monotherapy |
| Cohort D: Previously Treated RCC | EXPERIMENTAL | BGB-A445 and Tislelizumab |
| Cohort E: Previously Treated Melanoma | EXPERIMENTAL | BGB-A445 Monotherapy |
| Cohort F: Previously Treated Melanoma | EXPERIMENTAL | BGB-A445 and Tislelizumab |
| Cohort G: First Line Cisplatin Ineligible UC | EXPERIMENTAL | BGB-A445 and Tislelizumab |
| Cohort H: First Line Non-mucosal Melanoma | EXPERIMENTAL | BGB-A445 and Tislelizumab |
| Cohort I: Previously Treated Non-mucosal Melanoma | EXPERIMENTAL | BGB-A445 and Tislelizumab |
| Name | Type | Description |
|---|---|---|
| BGB-A445 | DRUG | administered intravenously |
| Tislelizumab | DRUG | administered intravenously |
Key Inclusion Criteria: 1. Participants who were histologically or cytologically confirmed advanced and/or metastatic cancer. UC participants (Cohort A and B), RCC patients (Cohort C and D) or melanoma participants (Cohort E and F) who have received at least 1 but no more than 3 lines of prior syst...